

Revolutionizing Chronic Disease Management with Precision Medicine and Navigating

Maria NAZIR

Hameer Khan KHASKHELI

Nighat BATOOL

Rumaisa NAWAL

Minal HUSSAIN

Danish RIAZ

Shafeeq Ur Rehman

Muhammad SAFDAR

1. Introduction

Chronic disease is recognized as an illness that takes a long time to develop and never has a short duration of occurrence they are dangerous to the global community's health (Who & Consultation, 2003). This rank includes a broad spectrum of diseases like Cardiovascular diseases, Cancers, Diabetes, Chronic respiratory disorders, Mental illnesses, etc. Chronic diseases have become common about 71% of all deaths are attributed to chronic diseases. First of all, they are accompanied by a high level of mortality and non-trivial rates of morbidity, and second, they cause inexpressible pain and significant material losses for people, families, healthcare facilities, and states (Fitzgerald et al., 2020). Chronic disease management refers to an extensive procedure. The conventional ways of approaching ideas, as well as ways of handling and managing a problem, have not been effective; whereby one has to wait for indications that a problem exists and apply standard means to many patients regardless of their differences. In such cases, these methods fail to consider the biophysical social environmental, and behavioral factors linked to chronic illnesses. This may result in patients experiencing difficulties in their quest to receive therapies and interventions that are more appropriate to their clinical condition based on other factors in the patient's case (Reichenberg & Seligman, 2016). They are exposed to suboptimal medicine, having to dig deeper into their pockets to pay for their treatment, and ultimately have a low quality of life. To counter these restrictions, the philosophy of Precision Medicine is saliently emerging as what is believed to be a brighter future in managing conditions (Duncan et al., 2021). However, when referring to the concept, precision medicine stems from the premise that people are not the same and hence, are genetically different from other individuals, have a unique history regarding their exposure to several factors, and have unique lifestyles (Figure 1). Therefore, the integration of genomics, proteomics, metabolomics, and other data analysis technologies for precision medicine enables suitable interventions that meet each person's needs (Singh et al., 2023). The provided approach can be viewed as the approach to change the formation of disease prevention, early diagnosis, further diagnostics, and management, and thus, it is possible to promote the healthcare system as well as enhance patient results.

Thus, precision medicine cannot be implemented in a way that will be effective without reconstructing the environment through which health care is currently delivered. It means a shift from the linear model of public health interventions to individualized medicine in the setting of the massive amount of information arising from the implementation of technologies in Medicine (Clim et al., 2019). This definition entails utilizing clinical data, genomics, wearable applications, and other data for a patient's health to create a patient picture. Therefore, the utilization of this information can be immensely advantageous as it helps the respective authorities in medicine supply

the appropriate centers with far superior treatment strategies (Moon et al., 2011).




Figure 1: Traditional vs. Precision Medicine in Chronic Disease Management

It can be adapted according to the expectations of the patient, enhance the number of successful cases, and ultimately reduce expenditures within a certain time. The chapter will discuss care navigation to determine how it would enhance the right application of precision medicine or the patient-centered care that patients would have to embrace together with chronic illnesses that each patient would have to live with during the duration of this study. Both precise medicine and care coordination of chronic disease are the real visions of the future for the healthcare industry of progressive patient-centered care that is efficient and, most importantly, financially sustainable.

2. Understanding Chronic Diseases

Chronic diseases, such as those that last for one year or more, are a recurrent public health occurrence. This broad category includes many syndromes of different etiologies, but they all have many things in common. They are chronic, have slow progression, and have multiple factors behind them (Table 1).

Table 1: Chronic Diseases: A Global Burden

Disease	Prevalence (Global)	Main Risk Factors	Economic Burden (USD Billions)	References
Cardio-vascular Disease	32%	Unhealthy lifestyle (smoking, diet, inactivity), high blood pressure, cholesterol	\$1,044	(Bovet & Paccaud, 2011)
Cancer	10%	Tobacco, unhealthy lifestyle, carcinogens	\$439	(Bode et al., 2016)
Chronic Respiratory	6%	Smoking, pollution, occupational hazards	\$383	(Viegi et al., 2001)
Diabetes	9.3%	Unhealthy lifestyle, genetics	\$327	(Arokiasamy et al., 2021)
Mental Disorders	Varies	Genetics, stress, trauma, social factors	\$2,500	(Muir & Zegarrac, 2001)

2.1 Common Chronic Diseases

Among the most prevalent chronic diseases globally are: These are the principal chronic conditions:

Diabetes: Initially, this is a metabolic disease that leads to high blood sugar levels, and to the present day, has affected over 420 million population (Ning et al., 2022). It is associated with presenting with cardiovascular diseases, peripheral neuropathy, nephropathy, and retinopathy among others.

Cardiovascular diseases: Coronary artery diseases, stroke, and heart failure are some of the diseases that constitute NCDS and they are among the main causes of death worldwide. Thus, hypertension, dyslipidemia, smoking, and physical inactivity are considered to be the factors that are potential determinants of the condition; however, other factors are considered to be detrimental to the situation (Matei et al., 2018).

Cancer: An account of diseases that involve the uncontrolled growth of cells and the spread of tissue; there are numerous types of cancers differing in results and management (Souhami & Tobias, 2008).

Chronic respiratory diseases: Other diseases, including COPD and Asthma, caused by cigarette smoking and other pollutants, cause extreme ill health and deaths all over the world (Gan et al., 2022).

Mental health disorders: This explains that typical mental disorders, including depression, anxiety, bipolar condition, or any other related disorders that drastically affect the quality of living of a patient, also have a lasting impact on the physical and overall health of a patient (Young & Grunze, 2013).

2.2 Chronic Diseases and Its Impacts on the Health and the Wealth of the Nation

Resolution with chronic diseases and illnesses involves pain in the social, psychological, and economic, as well as in the physical domain since chronic diseases transcend healthcare facilities, cultures, and borders. One of the most significant health risks in most countries, contributing to the cost aspect of health care systems, is complications due to chronic diseases since they form the largest component of health care costs. This condition also leads to low-quality work, work absenteeism, and premature death, making this a fiscal burden to most families and societies (Antczak & Miszczyńska, 2021). Also, with more patients getting affected by chronic diseases, the problem that arises is how one manages the same for a long time, which is demanding, sophisticated, and

resource-intensive.

2.3 Defects of the Traditional Model of Chronic Condition Management

In their view, while the conventional disease management models offer the required primary care for chronic diseases, they fall short of offering sufficient and comprehensive care for modern-day health needs. These approaches frequently rely on:

One-size-fits-all models: This indicates that treatment plans utilize some label and do not factor in each patient's genetic makeup and the environment they live (Squassina et al., 2010), as well as their lifestyle likely to enhance their susceptibility to the disease and the rate of the disease's progress.

Limited patient engagement: Another important implication is that patients' decision-making regarding affairs that influence their care may not be well exercised (Blustein, 1993).

Fragmented care: Numerous specialists can treat chronic disease, and there is little communication between providers, which results in fragmented care (Cortis et al., 2016). These challenges, therefore, justify why chronic disease management has to move away from this previously described traditional model of care and opt for a modern, patient-centered, proactive model of care. As for the shortcomings mentioned above, precision medicine and care navigation can be regarded as solutions that can help eliminate those negative tendencies and significantly improve the quality of life in patients with chronic diseases.

3. The Concept of Precision Medicine

Precision medicine as a concept and a form of delivering care in the healthcare sector can be classified as new, and it is described as the method used in the prevention, diagnosis, and treatment of disease based on characteristic features (Dugger et al., 2018). This is because to treat patients affected by diseases, one has to recognize the importance and uniqueness of every individual in genetic make-up, social backgrounds, behaviors, and manifestations of the illness. Thus, concerning these factors that may differ for any particular patient, precision medicine is constructed as the attempt to supply treatments that have better results and fewer side effects than standard treatments for any patient that may receive it.

3.1 Definition and Principles

Precision medicine could be described as the approach toward patients with diseases by which the medical approach is methodologically different, relying on the patient's genes, environment, and lifestyle (Gray et al., 2020). Since the 'blanket' form of treatment is conventional, or for a considerable period has been conventional, let us, precision medicine recognizes the differences in human biology and, thus, also in diseases and does not treat each patient as if his or her condition is similar to the other patient. The fundamental principles underpinning precision medicine include: The key ideas or the foundations of precision medicine comprise:

Individual variability: They know that advanced precision medicine patients are not the same; hence, failure to respond the same to certain treatments may be due to differences in genotypes, environment, or even lifestyle (Kaur et al., 2017).

Molecular profiling: This is the process through which the biomolecules of a person are sequenced; this person profiles the proteomes and metabolomes. This information can contain genetic drift, molecular change, and even other aspects concerning patients' ability to contract the disease, its progression, and subsequent treatment (Aranda-Anzaldo, 2001).

Targeted therapies: Precision medicine pulled the treatments that were being offered and administered from the molecular data of the person's illness and the molecular profile of the person in particular. This will be particularly helpful instead of the usual conventional treatments that are

normally toxic to the body (Stephenson, 2011).

Data-driven decision-making: Precision medicine is dependent on the theories holding that large quantities of data are sourced from patients, their records, and other sources such as EHRs and genomics. That information allows healthcare providers to develop association relations that are useful in the creation of individualized therapy (Bush et al., 2020).

Patient-centered care: However, what must be taken into account is that precision medicine is empowered by patients' engagement in decision-making processes. This way, a patient can receive data on their recovery state and possible therapies and then select the treatment that is consistent with their values and preferences (Knoepke et al., 2022).

3.2 History and Development

The essence of PM began much earlier than the term's coinage, less than two decades ago (Table 2). Physicians observed patients' behavior centuries before the present time, saying that patients' reactions are variable even though they are physically ill in the same manner, and thus, it is unethical to treat all patients in the same manner based on their judgment of the matter. However, with the introduction of the scientific technology of molecular biology and genomics in the late twentieth century, the concept of precision medicine got a new look (Cardon & Harris, 2016).

Table 2: Milestones in Precision Medicine

Era	Milestone	Significance	References
Ancient Medicine	Personalized medicine based on observation	Laid groundwork for individualized treatment.	(Issa, 2007)
19th Century	Discovery of blood types	Enabled safe blood transfusions.	(Biro, 2022)
Mid-20th Century	Pharmacogenetics (genetic variation in drug response)	Tailored drug therapies to individual patients.	(RAMEEZ et al., 2023)
1990s	Human Genome Project initiated	Paved the way for genomics-based medicine.	(Olson & Berger, 2012)
2000s	The Human Genome Project completed	Identification of disease-related genetic markers.	(Mundy, 2001)
2010s	Rise of precision medicine targeted therapies for genetic mutations	Personalized treatment for cancer and other diseases.	(Jäger et al., 2021)
2020s & beyond	Advancements in genomics, proteomics, metabolomics	More comprehensive personalized treatment approaches.	(Su et al., 2021)
Future	Integration of AI and big data analytics	Refined precision medicine and improved disease prediction and treatment response.	(Sahu et al., 2022)

The Human Genome Project sequenced all the genes of the human body, an effort acclaimed for putting at the disposal of mankind all the codes that one would require to construct, sustain as well as repair the human body (Gannett, 2008). One of the major findings was biomarkers, to which further invention of diagnostic machinery, proper treatment, and tailored treatment plans were added in later years. Since then, great advances have been made in precision medicine because of available technologies such as genomic sequencing, bioinformatics, and data analysis. Earlier, the funding for genomic sequencing was high; it was not feasible for clinical uses, but it has revolved (Kwong et al., 2015). Thus, the number of genetic alterations that cause diseases has been determined.

3.3 Key Components: Genomics, Proteomics, and Metabolomics

Precision medicine applies a top-down approach of multiple levels of molecular characterization of a patient, which allows for a better overall reflection of the patient's condition. The key components of this approach include: While adopting this approach, some of the aspects include:

Genomics: On the other hand, is a branch of science that deals with an individual's complete genetic makeup or the analysis of all the genes. Genetic information may point to the exact gene that is involved or affected in some disease or specific changes that cause the said individual to point to specific diseases or reactions to certain other therapies (King et al., 2002). Therefore, the second generation of sequencing techniques during the last few years has helped to realize the idea of individual DNA rapidly and cheaply, which enhanced the actual implementation of the concept of personalized medicine.

Proteomics: Regarding proteomics, it is possible to give a relatively straightforward definition of this term that can be stated as such. This discipline is large-scale research of proteins of an organism or a certain cell. Since proteins are the functional molecules within a cell, with people's body's workforce being employed by the cell most, it can only be that the concentration and activities of these proteins can become an area of concern in disease processes. Proteomic analysis can, therefore, offer biomarkers relating to the disease diagnosis and, additionally, the potential severity and reaction of the disease to the treatment plan (Bowser & Lacomis, 2009). Therefore, if one comprehends how proteins are employed in diseases, that person can develop cures focusing on such irregularities.

Metabolomics: Therefore, it may be defined as the sub-discipline of the biology involved with identifying small molecules referred to as 'metabolites.' It is specified that metabolites are the final career products of metabolism, and their concentration denotes an individual's physiological condition and disease condition. Metabolomic analysis can determine disease risk factors, prognosis indexes, and treatment effect evaluation and unveil the pathogenesis of the diseases (Gonzalez-Covarrubias et al., 2022).

4. Interventions tailored for patients in Chronic Diseases Management

Precision medicine is revolutionizing the management of chronic diseases right from its premise of generalizability in one population to that of individual special nongranular treatment as applicable to every patient (Wouters et al., 2021). Thus, by using genetic profiling, individualized treatment and therapy, and biomarker-based outcome control, there are great advancements in the diagnosis as well as treatment of illness and diseases, resulting in greater effectiveness and efficacy of prognosis for patients and the healthcare system as a whole (Figure 2).




Figure 2: Personalized Chronic Disease Management

4. 1 Genetic profile and risk prediction

In personalized medicine, genetic profiling is a procedure that aims to analyze all the genome characteristics that point to risk factors, disease development, and treatment outcomes (Goulielmos et al., 2016). Through the demystification of the human genome, which includes diseases that may run in one's family as well as their odds of developing a myriad of chronic illnesses, healthcare practitioners can improve the odds of predicting diseases prone to affect a particular patient and the preventive measures to be taken.

Cardiovascular Disease: Polygenic risk scores, calculated based on multiple genetic variants, recently came into light as one of the most effective tools for estimating the particular patient's risk of the development of coronary artery disease (Gladding et al., 2020). Thus, clinicians can advise clients to change their dietary habits or to engage in physical activity; in high-risk clients, counsel them to start on statins to decrease the risk.

Cancer: DNA bio-markers such as the BRCA1 and BRCA2 genes can be tested, and it identifies customers or group members that are at a very high predisposition for contracting breast and ovarian cancer (Holman, 2014). Such knowledge can be used for individual risk management to reduce risk or the subsequent measures that may save lives if early detection, preventive surgeries, or medication with chemopreventive effects are indicated.

Neurodegenerative Diseases: Specific loci of the APOE gene coded for ApoE have been shown to have a significant linkage to the development of ADR (Cacabelos et al., 2010). Currently, no definitive cure exists for Alzheimer's, but high-risk people's early identification can aid in enrolling them in cognitive maintenance programs or experimental treatment hypotheses to perhaps postpone disease development or contraction.

Pharmacogenomics: The researchers that differences between people may be mitigated because genetic differences affect drug use. Pharmacogenomic testing involves stratifying genetic markers that would point out the effectiveness of drugs and the risk of adverse reactions (Tzvetkov

& von Ahsen, 2012). Thus, clinicians would be able to select the right drugs or dosages for patients, improving healthcare outcomes with fewer cases of drug intolerance.

4. 2 Individualized Treatment Programs and Exercising

Precision medicine helps create individual treatment programs that are targeted to the molecular and genetic profile of a particular disease in the patient. This approach ensures optimal treatment response is achieved without undesirable side effects, hence enhancing the clients' progress and utilization of Health resources.

Oncology: Targeted treatment involves directing the treatment to the particular molecular alterations that make tumor cells grow rapidly. It has improved the management of several cancers. For example, patients with HER2-positive breast cancer are administered trastuzumab, which is a monoclonal antibody that corresponds to the HER2 receptor, meaning that it helps boost the rates of survival among those patients (Patel et al., 2020).

Inflammatory Diseases: Inflammatory Diseases: Biologic agents such as TNF-alpha inhibitors and IL-12/23 inhibitors have greatly transformed the approach to chronic inflammatory diseases from RA to IBD (Argollo et al., 2019). These therapies act specifically on the disease's cytokine production, and therefore, they are more effective in controlling the disease than broad traditional medicines.

Rare Diseases: The approaches of precision medicine have created new horizons for diagnostics and therapies for rare diseases with genetic backgrounds. That is why molecular diagnostics, identifying exact loci with certain mutations, allow the creation of specific therapies and gene therapies when the previous potential of medical treatment for patients with rare diseases was limited (Marwaha et al., 2022).

4.3 Role of Biomarkers in Monitoring and Prognosis

Biochemical markers indicative of a disease state are important to the intervention of precision medicine. They can be used to:

Monitor Disease Progression: Because biomarkers are measurable, they can be used by clinicians over a given time as markers for determining the impacts of the treatment plan given, detecting any signs of disease progression or relapse, and with this, making necessary changes as needed. For instance, glycated hemoglobin (HbA1c) is used in diabetes to evaluate the patient's overall glycemic control and to compare with the risk indices for complications (Kohnert et al., 2015).

Predict Treatment Response: Some of the biomarkers can help one understand his/her chances of having and responding to a particular type of therapy. Thus, the obtained data can be suitable for choosing therapy in which the patient would receive therapy potentially positively affecting their condition. For example, in breast cancer, the status of estrogen and progesterone receptors helps to determine the reaction to hormone treatment (McGuire et al., 1977).

Assess Prognosis: Biomarkers can provide a lot of information regarding the severity of the disease and its likely prognosis, which can be helpful in prognosis and decision-making concerning the aggressiveness of the therapy to be applied, if any. For instance, in heart failure, a higher concentration of brain natriuretic peptide (BNP) indicates poor prognosis, and hence, other drastic measures may be warranted (Sarhene et al., 2019). By incorporating a person's genes, specific treatments, and biomarker-based follow-up, it has substantially transformed the management of chronic diseases. This approach hands the control of patient care back into the hands of healthcare givers, where it rightfully belongs. Such an environment has exacted, timely, and anticipatory care delivery that results in better patient well-being and increased efficiency of the healthcare delivery system.

5. Technologies Enabling Precision Medicine

This discipline is in its embryonic stages, and more importantly, it heavily depends on technologies that enable the generation, extraction, and processing of big data, particularly from patients. In addition to offering increased insight into disease etiology, these technologies are also reshaping the way with which several chronic conditions are diagnosed, managed, and treated, thus creating the foundation for the development of novel and progressive, individualized approaches to medicine.

5.1 Next-Generation Sequencing (NGS)

Next-generation sequencing (NGS) is a current revolution in bioinformatics in the progressing healthcare system, which can hand over whole-genome sequencing or particular selection sequences within a reduced time and cost (Satam et al., 2023). This has helped to expand the opportunities and ability to determine the genetic variations linked with the presentation, prognosis, and management of disease, allowing for the basic of targeted treatments (Figure 3).




Figure 3. Unveiling the NGS tool of Precision Medicine

Disease Risk Assessment: The polygenic risk scores, made possible by NGS, integrate the effects of many genetic features and allow estimation of an individual's probability of developing complex disorders (Slunecka et al., 2021) including coronary artery disease, type 2 diabetes, and some forms of cancer. That is why this information can be used to sort people according to their risk and further provide them with preventive measures and early treatment.

Diagnosis: NGS can be used to identify most diseases, but it has found significant application in cancers and certain rare genetic disorders. Because NGS can detail certain genetic changes or fusion genes, it can be used to properly choose the right EPs and assess the patient's prognosis (Lanza et al., 2020). In most advanced cancers, there is a growing application of NGS-based tumor profiling to identify druggable mutations that can be readily treated to enhance patients' survival (Shibata, 2015).

Treatment Selection: Pharmacogenomics, one genre of application of NGS that studies the genes associated with how a patient metabolizes medications and how he or she responds to them,

is changing how we choose drugs for patients (Schwarz et al., 2019).

5. 2 Bioinformatics and BIG Data Analysis

The amounts of data produced by NGS and other omics technologies can only be analyzed and transformed into useful information with the help of robust bioinformatics algorithms and big data analytical approaches. It is well understood that exact and accurate algorithms and software are involved in analyzing genomic data, differentiating disease-related variants, and assessing them for their functional implications (Liu et al., 2022). Such tools can highlight genetic variants and estimate their effects on the proteins and even on their pathogenicity. In contrast, big data analysis uses machine computation and mathematical formulas to seek relationships in the big data set (Adadi, 2021). Approaches of this type can be employed to discover new biomarkers for diseases, new therapeutic targets for treatment, and assign disease risk and treatment outcome prediction models. The sub-field of big data analytics, namely machine learning, is expected to be employed to provide a more detailed understanding of the disease processes and patient paths. With the help of analyzing electronic health records, genomics, and other sources of patient information (Ohno-Machado et al., 2018).

5. 3 Wrist-worn Technologies and Mobile Healthcare (mHealth)

Mobile healthcare technologies and wearable devices are considered to transform chronic disease management by enabling patients' self-management (Stampe et al., 2021). It also supports the clinician's timely decision-making process. Some of the indicated devices include but are not limited to A fitness tracker, a Smartwatch, and a continuous blood sugar monitor Among other physiological and behavioral information that the devices may capture and aggregate are; heart rate, blood pressure, physical activity, quality of sleep and among others regarding the medicine (Figure 4).




Figure 4. Unveiling the wearable tool of Precision Medicine

This continuous data is very useful in assessing the health state of a given individual, the prognosis of a disease, and the impact of management interventions. For instance, patients with diabetes can employ advanced devices such as continuous glucose monitors available to show their glucose levels in real-time, making it possible for a patient to adjust their insulin dose or change their diet. Likewise, hypertensive patients can use home blood pressure monitoring using wearable

equipment that helps them detect changes in blood pressure and help alter the medication schedule accordingly (Rastegar et al., 2020). Mobile health apps can increase the knowledge of patients about their conditions and possible ways for their treatment and, thus, improve the management of chronic illnesses (Piette et al., 2015). The mentioned apps can include features such as taking medicine on time, giving out information, helping track symptoms, and arranging an online appointment with a doctor. Offering patients mHealth technologies can help to improve the schedule of treatments and to increase the compliance of patients, which in turn can increase the levels of disease control and, ultimately, the quality of health outcomes.

6. Case Studies: Applying Precision Medicine

The potential of precision medicine is perhaps better illustrated in use-case scenarios that tell the success story of how patients' lives changed for the better with this new approach to disease care. Further, considering real-life cases will be informative. It will be informative to discover how this individualized approach is transforming the sphere of healthcare and enhancing patients' results.

6. 1 Diabetes Management: Personalised Insulin therapy

Diabetes mellitus, particularly its type 1 and 2 with high blood glucose levels must be closely supervised to avoid effects (Perkins et al., 2021). Classically, insulin treatment has been formulated by trial and error with the help of blood glucose data and patients' testimonials. Nevertheless, this concept is changing with the help of precision medicine that utilizes genetic data for Insulin therapy. For instance, macro genetics analyses of RCTs have found genes that determine insulin sensitivity and secretion, which can be used in the assessment of the given individual's response to various types of insulins (Jaacks et al., 2012). Clinicians genotype patients for these variants that help in personalizing insulin therapy based on the type of insulin, dosage, and frequency of administration. It can enhance glycemic control, decrease the incidence of hypoglycemia, and extend patients' life expectancies in diabetes mellitus. Furthermore, there is also the modern CGM, integrated with machine learning systems; currently, these are used to create closed-looped insulin delivery systems during which the bolus and the basal insulin doses are prescribed based on the current glucose levels (Mohebbi, 2021). For this reason, the 'artificial pancreas', therefore, holds the prognosis of modifying and managing the diabetic patient since through it, the body requisites of insulin are determined, and the amount of the hormone that is administered is regulated without much participation from the patient.

6. 2 Cardiovascular Diseases

In the greater majority of types of cardiovascular pathologies, the leading causes of death are chronic, and ought to be treated as such, minimum, for the remainder of one's days. Treatment is becoming enriched in such a way through precision medicine concerning the prescription and consumption of drugs through the patient's genotype (Singh, 2020). Regarding the application of pharmacogenomics in the use of drugs filed under the individual patient category, the best example is the use of warfarin. The anticoagulant warfarin is a drug well included in the list of drugs with many gene interactions varying by patients' genetic polymorphisms in the CYP2C9, and VKORC1 genes (de Freitas Campos et al., 2023). By genotyping the patients for such variants, the clinicians who will administer the drug will be able to determine the patient's response to warfarin and give the first dose in the right measure that will not cause bleeding-related side effects, thus enhancing the effectiveness of the media even on patients with comorbidity disorders. For instance, the test for genetic screening of the population to detect persons with FH, which is a hereditary disease that leads to high levels of LDL cholesterol (Berberich & Hegele, 2019). FH can also be tested genotypically; therefore, patients can begin taking lipid-lowering drugs, including statins and PCSK9 inhibitors, to attempt to minimize cardiovascular diseases.

7. Case Studies

The use of insight in the engineering of precision medicine applies to every domain of chronic diseases. Let's delve deeper into two specific areas where precision medicine has made significant strides: cancer patients who are going through chemotherapy as well as other individuals who have chronic diseases of the respiratory system.

7.1 Cancer Treatment: Targeted Therapy and Immuno-therapy

Cancer is a systems genetic and intra-tumor retreating molecular heterogeneous disease that previously was treated with broad interventions such as chemotherapy and radiotherapy, which has severe side effects (Kwapisz, 2022). Precision medicine has now brought about the concept of targeted therapy and immunotherapy, which envelopes the identity of molecular characteristics of each tumor of each patient.

Targeted Therapies: Such therapies are meant to deprive certain critical molecules or pathways for cancer cells' survival and growth. For example, patients with chronic myeloid leukemia (CML) with the BCR-ABL1 fusion gene can receive tyrosine kinase inhibitors (TKIs) such as imatinib due to the specificity of the latter for the identified oncoprotein (De Novellis et al., 2021). Likewise, lung cancer patients who were positive for EGFR mutation can be treated with EGFR inhibitors that have shown an increased survival rate compared to conventional chemotherapy (Tang et al., 2019).

Immunotherapy: This approach works based on the principles of immunology to eliminate the existence of cancer cells. Generally, immune checkpoint inhibitors, including PD-1, and CTLA-4 inhibitors, have been described as having high success rates in the eradication of different cancer types, including melanoma, lung, and kidney cancer (Wojtukiewicz et al., 2021). Cytotoxic therapies are effective in removing the suppressive messages circling in the body, which would otherwise prevent the immune system from attacking the cancer cells.

7.2 Chronic Respiratory Diseases

Two of the long-term respiratory illnesses are diseases resulting from various causes that have characteristic manifestations such as asthmatic and chronic obstructive pulmonary diseases. Precision medicine is raising awareness of such diseases and helping to create improved diagnostic and treatment solutions.

Precision Diagnosis: Molecular phenotyping with gene expression patterns and protein biomarkers, as well as inflammatory mediators, is growing to be implemented with patients with asthma and COPD to differentiate subgroups (De Ferrari et al., 2016). This enables better diagnosis and identification of the set of patients who gain more benefits from these treatments. For instance, patients with eosinophilic asthma comprising increased eosinophils in the bronchi have benefited from IL-5 antagonists (Roufosse, 2018).

Precision Treatment: Global control strategies for asthma and COPD involve the use of ICS as the 'gold standard,' but there is a large variability in response to these treatments. The pharmacogenomic research reveals the genetic factors that affect the ICS's efficacy and, therefore, explains why certain patients benefit more from ICS than others (Matera et al., 2017). This knowledge can then be applied by clinicians in choosing the right ICS dosage and form for the patient's case.

Personalized Management: Thus, precision medicine is also opening the prospects for individualized control of chronic respiratory diseases with digital health and wearable technology. It is possible to have tools that can gather data in real-time regarding the patient's lung functioning, medication intake, and severity of symptoms allowing the clinician to assess disease progression and adjust the course of action as necessary (Mackay et al., 2018). Precision medicine is slowly revolutionizing the way that chronic diseases are being handled, especially in the treatments being offered. Several examples include diabetes (personalized insulin therapy), cardiovascular diseases

(genotype-based drug diets), cancer (genotype-based therapy and immunotherapy), and chronic respiratory diseases (precision diagnosis and treatment) (Villagómez-Guzmán & Quiroz, 2024). With these examples, the application of precision medicine has the potential to change how patients are managed, resulting in better outcomes.

8. Implementing Precision Medicine into Practice

Precision medicine adopts a broad and complex concept, which can be implemented in various approaches and tackle different issues according to the adaptation and utilization of precision medicine in routine clinical practice. It entails policy and practice advancements that enhance safety and exert multi-professional collaboration and education with patients to enhance the benefits relevant to this new conceptual model of healthcare.

8.1 Implementation Strategies and Best Practices

Implementing precision medicine in clinical practice requires a well-structured approach that addresses key considerations: subfactors referred to in this article in clinical practice of PM which consist of the following:

Infrastructure and Resources: It has been briefly pointed out that constructing the capacity that forms the basis for genomics involves using appropriate generic sequencing technologies, assembling bioinformatics teams, and setting up storage and analysis datasets. These resources are critical in creating and analyzing big data from genomics and clinics, which is the basis of precision medicine (Xue et al., 2016).

Clinical Decision Support Tools: Precision medicine data must be incorporated into EHR, and CDS tools must be created to be easily implemented in regular clinical practice (Sitapati et al., 2017). Computerized decision-support systems enable clinicians to receive alerts and recommendations on a patient's risk level and the appropriate treatment plan depending on the genomic makeup.

Education and Training: Education and training are crucial components of enhancing PM, and healthcare professionals need extensive programs. Such training involves precision medicine, genetic counseling, genomics interpretation, and other forensic-related challenges and ethical issues from genomic information in clinical practice (Alshehhi et al., 2023). Relevant continuous professional development programs can demonstrate that healthcare providers are in touch with the advancements in the sphere.

Reimbursement and Policy: Existential issues such as policy formulation and reimbursement models that compel the use and procurement of PM also affect technology adoption (Muthelo, 2022). This might include the inclusion of genetic testing, targeted therapies, precision medicine, and other relevant treatment services by health insurance companies. Also, the policies and infrastructures for sharing and cooperation between different healthcare organizations can help to create more extensive datasets needed for the development of precision medicine and its applications.

8.2 Features of Research and Setting of Programs

In managing chronic conditions, patient-centered interprofessional care teams are usually formed by the PCP, specialists, nurses, pharmacists, social workers, and other stakeholders (Mohiuddin, 2020). Such an integrated care model may be especially valuable for patients with chronic disease co-morbidity, facilitating the communication between different healthcare providers, consistent assessment of patients' medication lists, and overall coordinated co-management of coexisting diseases.

8.3 Role of Healthcare Providers and Patient Education

Physicians remain the linchpin in translating precision medicine into a reality in the wards, clinics, and operating theaters. They also should be up to date regarding the progression of precision

medicine, existing genetic tests, intentionally targeted therapies, and other clinical support systems. Also, they should be able to explain the complicated genetic information to the patient concisely and easily understandable, thus equipping the patient with sufficient information to make the necessary decisions regarding her treatment. Lack of adequate knowledge about the diseases is one of the major shortcomings that can be overcome by educating the patients through pamphlets that they can take home, videos, and genetic counseling.

9. Ethical, Legal and Social Issues

9.1 Ethics of genetic testing and data privacy

Some of the key issues of ethical concern being highlighted by the use of genetic testing include the patient's control and self-determination, the autonomy of the patient, and the notion of the patient's consent.

Autonomy and Informed Consent: Patients must be free to make certain decisions as professionals or not to take certain tests such as genetic testing. Thus, any genetic test must be preceded by the patient's informed consent, where they are to be informed of the test's purpose, its possible risks and benefits, and any possible outcome that may arise (Green et al., 2004). It involves dimensions such as medical geneticists' approaches to alert patients and their families of incidental findings and how they would address findings in genetics not relevant to the reason for testing.

Genetic Discrimination: The concern over job, insurance, or other social preconceptions arising from a person's genetic profile continues to be a concern among many people (Lovejoy, 2000). Measures such as GINA, Genetic Information Nondiscrimination Act in the United States offer some antidote, but questions arise on the possibility of these laws containing holes that may be exploited by one form of discriminative technique or the other, and the general need for stronger legal frameworks to curb discrimination based on genetic results.

Data Privacy and Security: Precision medicine requires the collection and analysis of large quantities of a patient's genetic and personal health information that is considered private and confidential, thus increasing the risk of privacy and security breaches (Li, 2016).

9.2 Legal Environment and Related Issues

The rapid pace of technological advancements in precision medicine has outpaced the development of legal and regulatory frameworks, posing several challenges: Consequently, the integration has led to several challenges highlighted here below due to the alarming rate of technological advancements in precision medicine as opposed to the formulation of legal and regulatory measures.

Intellectual Property Rights: Concerns connected with the patenting of genes and approaches to diagnostic techniques and therapies can cause some limitations in access to medicine and slow down advancement (Arjmand et al., 2020). It is still challenging to achieve an appropriate level of encouraging further research and development and accessible precision medicine in terms of law and policy.

Regulatory Oversight: Writing that addresses the presently prevailing actual-law frameworks for precision medicine needs to be mindful of three important facts: The use of new genomic tests and targeted therapies must be protected to avoid any safety or efficacy issues, yet the rapidly growing technologies surpass the approval processes (Phillips et al., 2018). Issues of interest include the ever-raging debate on how to foster innovation while at the same time protecting the lives of the patients.

Liability and Malpractice: Such employment of genomic information in clinical practice leads to many concerns concerning liability and medical malpractice (Pike et al., 2014). If the

patient gets an adverse outcome from incorrect genetic analysis or the absence of appropriate genetic markers, then defining fault for it is challenging. This means that there is a need to have clear-cut guidelines and standards that have to be followed regarding the use of genomic information in clinical practice to minimize the risks.

9.3 Accessibility and Social Equity Problems

It is, therefore, extremely relevant to consider the ethical and social implications of the achievement of precision medicine, particularly concerning the ideal of fairness in the distribution of the interventions in question.

Cost and Affordability: Targeted therapies and genetic testing can be costly and, therefore, out of reach for many people, especially those with low incomes or insufficient insurance coverage (Adachi et al., 2023). If precision medicine widens the gap between the 'haves' and the 'have-nots,' as indicated in the case of cost barriers and affordability, then it will further users' woes.

Health Disparities: This is because precision medicine is pointed out to pose a threat of increasing existing inequalities in health outcomes (Vodovotz et al., 2020). Clinical studies in specific diseases and their treatment require ethnically and racially diverse sample participants to guarantee that precision medicine outcomes will not be sensitive to race, ethnicity, or socioeconomic status.

Public Understanding and Trust: Precision medicine is now embodied in the broader context of personalized medicine that designs individual treatments based on characteristics that encompass not only genes but also other facets of an individual's life; therefore, for people to have confidence in this paradigm, veterinarians must make it transparent, educate and engage. The general population also requires knowledge about the opportunities and challenges of precision medicine and the moral and social impacts of the approach to make a rational choice regarding their overall health (Maeckelberghe et al., 2023). Therefore, dissecting the components of the final ethical, legal, and social implications question is critical to properly and fairly implementing precision medicine. When these challenges are preemptively solved, precision medicine promises to revolutionize healthcare to the advantage of all people.

10. Precisely, Managing the Future of Precision: Medicine

With the advancement of precision medicine, the latest trends and new advancements or inventions are said to bring greater change to the management of chronic ailments. This future trajectory includes such specifics as the application of the newest technologies, such as liquid biopsies and single-cell sequencing, the establishment of artificial intelligence and machine learning, and increased focus on preventive and, at best, early-diagnosis approaches.

10.1 New Directions and Advances

Several promising trends are shaping the future of precision medicine and hold the potential to impact chronic disease management significantly: Several promising trends are shaping the future of precision medicine and hold the potential to impact chronic disease management significantly:

Liquid Biopsies: Blood or other body fluids-based liquid biopsies which comprise circulating tumor DNA (ctDNA), RNA, or other biomarkers are recognized as a tissue biopsy surrogate for cancer diagnosis, monitoring, and treatment choice (Shegekar et al., 2023). Lung cancer has been proven to be diagnosed at an early stage, identify the molecular residual disease, and evaluate the response to treatment in real-time with the help of this technology. In chronic ailments also, liquid biopsies could help in observing the status of the disease and the appearance of complications without always having to perform invasive procedures (Perales et al., 2021).

Single-Cell Sequencing: Thus, single-cell sequencing technologies that enable the assessment of the genome, transcriptome, or epigenome of individual cells reveal essential information about

cell heterogeneity and the pathogenesis of various diseases (Kamies & Martinez-Jimenez, 2020). The sort of analysis possible at this level can help to distinguish between healthy and diseased cells, discover rare populations of cells promoting disease, and discover new targets for therapies. In chronic illnesses, single-cell sequencing might allow additional insight into the interactions between different cell types and molecular apparatuses and, consequently, improve treatment strategies and practices.

Gene Editing Technologies: Gene editing tools such as CRISPR-Cas9 hold the promise of replacing a bad gene with a good one, meaning that genetic diseases have possible cures in the form of editing tools (Bhattacharjee et al., 2022). Despite being largely present only in research, gene editing could revolutionize the future of precision medicine, with rare inherited conditions possibly being treated in this way in the future.

10.2 AI and Machine Learning

AI and Machine learning are now significant tools that are becoming almost mandatory to work in precision medicine as these technologies help researchers and clinicians analyze the data and mine the patterns from these sets, which are difficult for humans to handle.

Image Analysis: X-rays, CT scans, and MRI can be analyzed with the help of algorithms enabled by Artificial Intelligence to diagnose complex and simple patterns within the images that may be out of reach of human eyes (Najjar, 2023). This can help in the early detection of different chronic illnesses such as cancer, cardiovascular, and neurological disorders, hence integrating early interventions to enhance performance.

Risk Prediction: Universal computing and AI used in the ML frameworks can combine multiple forms of data, from genomic data and electronic health records to environmental exposures, to create accurate risk estimate models for different chronic diseases (Zahid et al., 2021). Such models could pinpoint people who are most likely to get afflicted by certain diseases, allowing the application of measures to prevent the diseases early.

Treatment Optimization: Clinical and molecular data can be processed to create individual patient response profiles for various treatments that AI algorithms could use (Elemento et al., 2021). This information can assist in the choice of multiple treatment options that would increase therapeutic outcomes and reduce toxicity. AI technologies can also assist with tracking patients' responses to treatment in real time to make changes to the process and focus on patient-centered care.

10.3 Possible Preventive Medicine and Early Detection

It's one of the key strengths of the approach, where precision medicine has the potential of moving the healthcare system away from one that is fundamentally reactive to one that seeks to prevent diseases and intervene early when necessary. Special attention should be paid to genetic testing, risk prediction, and advanced diagnostics in achieving early identification of people who may develop chronic diseases in the future, which allows practicing the prevention needed for lifestyle changes and chemoprevention or early intervention. The advantages of this approach may consist in preventing or postponing some chronic diseases, thus providing better health and institutional results, not to mention decreased costs (Organization, 2013).

11. Challenges and Barriers

It is evident that precision medicine creates great promise; however, applying and offering precision medicine to the public equitably has some hurdles and obstacles. These are various challenges, which are technical, scientific, economic, and social, and that require involve of all the stakeholders in the healthcare organization (Table 4).

Table 4: Challenges and Barriers to Widespread Adoption of Precision Medicine

Barrier Category	Specific Barrier	Potential Solutions	References
Technical	Data privacy, standardization, interpretation, access	Encryption, universal formats, cloud storage, user-friendly tools, telemedicine.	(Akotaobi, 2023)
Economic	High costs, reimbursement, lack of incentives	Subsidies, insurance coverage, new payment models, partnerships.	(Ndayishimiye et al., 2023)
Social	Ethics, awareness, disparities, discrimination	Guidelines, education, equitable access, anti-discrimination laws.	(Scott, 2023)

11.1 Drag and Drop Environment

Despite the remarkable progress made in precision medicine, several technical and scientific hurdles remain: Despite the remarkable progress made in precision medicine, several technical and scientific hurdles remain:

Data Integration and Interpretation: The flow, heterogeneity, and complexity of data produced by genomic sequencing, proteomics, metabolomics, and similar techniques generate several issues related to data integration, analysis, and interpretation (Santiago-Rodriguez & Hollister, 2021). To transform this paradigm into a biologist's everyday reality, standardization of data formats, consistent bioinformatics resources, and intelligent ML models are the keys. Moreover, superimposing multi-omics data with clinical and environmental data needs considerable and compatible utility to organize the databanks, given the intricacy and heterogeneity of incoming data.

Unraveling Disease Complexity: Most chronic diseases are polygenic and multifactorial, meaning there are numerous interactions between the many genes, both in the inhabitants and their microenvironments and lifestyles (Butnariu et al., 2022). Acknowledging and comprehending such complex relationships is still one of the major scientific tasks. It has to be based on massive multi-center investigations, long-term data collection, and problem-solving methods that are novel in data analysis and modeling to uncover disease mechanisms and design individual-based risk prediction models.

Limited Clinical Utility: Although genomic information can offer many tangible data like the risk factors for disease or a candidate's reaction to treatment, it is not always easy to use in clinical practice (Suter, 2015). Most common genetic variants are associated with modest changes in risk, and the effects of those variants may be nuanced by the environment and lifestyle. Moreover, there is not adequate clinical evidence for many genomic tests and targeted therapies, which cannot be adopted at the clinical level. Additional studies are required to support the outcome of genomic results and develop standard protocols to implement them in medical practice (Alarcón Garavito et al., 2023).

Ethical and Regulatory Considerations: Warning issues of precision medicine include, but are not limited to, issues to do with informed consent, data privacy, genetic discrimination, and issues of incidental findings, again call for improved ethical scrutiny and guidance (Beskow et al., 2018). Maintaining a balance between embracing innovation and protecting the patient's rights and their privacy is quite a task in ethics. Further, the complex and shifting global regulatory environment should be aligned with the fast-growing options in Precision Medicine technologies for protecting the consumer as well as building trust and developing components of IP and Accessing healthcare.

11.2 Indicators; Barriers to Access and Quality Education: Economic and Financial Aspects

The challenges concerning precision medicine's cost and feasibility are diverse and significant; they affect the delivery of precision medicine to the population.

Cost of Genomic Testing: While the costs have reduced gradually over the years, it remains a very costly procedure that is unaffordable to the majority of people as well as healthcare facilities (Organization, 2007). This can lower the chances of the patients being given the genomic tests especially if they have no adequate insurance or belong to the minority groups. The fact that the accessibility of genomic tests is becoming a pressing issue implies that cost reduction, insurance coverage, and the creation of new types of financing are critical in terms of the organizational perspective.

Cost of Targeted Therapies: Although it was established that targeted therapies are normally more effective as compared to traditional approaches to treatment, these drugs are normally quite expensive (Waterhouse et al., 2006). These therapies have been known to be costly whereby they are inconveniencing to the patients, in addition to being costly to equip healthcare facilities hence leading to a lot of debates regarding its cost-effectiveness. Additionally, the long-term benefit of some of the incorporated targeted therapies is still not quite established and, therefore, efficient control.

Reimbursement Challenges: The payment of precision medicine is still uncontrolled, and the payment methods are not very similar. Most genomic tests and targeted treatments are not covered by insurance or not reimbursed. The standardization of insurance coverage for genomic tests is different depending on the insurance provider or available test/treatment options (Schoonmaker, 1998). Nevertheless, when insurance reimbursements are low and sporadic, they may become a problem concerning money on the patient's side and the future advancement of precision medicine in actual healthcare facilities.

11.3 The Health Care Disparities

Therefore, the most fitting illustration of the kind of distribution of healthcare that has been accused of being prejudicial to accessing quality care is when precision medicine reinforces socio-economic healthcare disparities (Singh, 2023). Medical racism is illustrated through guidelines related to who receives a genetic test, targeted treatments, and other aspects of precision medicine. To address these disparities, a concerted effort is needed. To overcome all these disparities, the following strategies have to be undertaken:

Increase Diversity in Research and Clinical Trials: This implies that people of diverse races, ethnicities, and SES should participate in research and clinical trials to ensure that safe and effective mechanisms of precision medicine are developed for each population group (Washington et al., 2023).

Improve Access to Genetic Counseling: Genetic counseling is very important because it entails patient education to underscore genetic test results for a mutually appropriate management plan (Burke et al., 2007). To address this challenge, patients must receive the care and attention they need to survive in precision medicine; therefore, more genetic counseling services must be made available to people in regions with limited services.

Educate Healthcare Providers and the Public: Hence, it is only clear to educate consultants and the public about the existence of precision medicine so that optimal outcomes are obtained from the technology and patients are informed about their right to choose. This entails that patients and the public receive information such as the benefits and risks of genetic testing, targeted therapies, and any other precision medicine intervention (Rose, 2013). These are the challenges or will be, together with the barriers that hinder precision medicine's offering exact use and contributing great

value to the healthcare system for patients with chronic diseases.

12. Conclusion

By the method of precision medicine, it has been further predicted that the control of chronic diseases is set to start being done in a different technique than the conventional technique of controlling diseases, and this is the traditional one-size-fits-all technique of controlling chronic diseases. Precision medicine makes use of genomic sequencing, multi-omics, intelligence with AI, and other uses, including mobile health technologies for the improvement of identification of the risk factors affecting an individual's disease, determination of the various personalized treatment options available for the addressed disease, and the utilization of applications of technology, as well as other available approaches for the prevention of the concerned disease that can be optimally utilized in a personalized manner. The case examples of precision medicine implementation that could potentially be seen throughout the given chapter and the case subject matter depict and exemplify the benefits of such an approach regarding the management of different chronic diseases diabetes mellitus, cardiovascular diseases, cancer, chronic respiratory diseases, and many others. Thus, implementing PM as one of the significant components of daily clinical practice is not entirely problem-free. Data integration and analysis still remain a problem, as well as comprehensiveness and heterogeneity of the diseases, problems in funding, and last but not least, regulatory, legal, and ethical issues are important problems that have to be solved by all the stakeholders. However, there is a positive prognosis for the application of precision medicine in the future. Technologies like liquid biopsies that are not currently part of the equation, single-cell sequencing, and more attractive gene editing technologies are new possibilities for enhancing the performance of individualized therapy. In addition, its usage will have a definite role to play when it comes to raising the rate of novelties in disease identification and treatment. To conclude, it is vital to note that more progress and rational utilization of precision should assist in equalizing access to it, and its ethical and social impacts are to be described and mitigated; interdisciplinary cooperation remains the most important goal for scientists, clinicians, patients, and policymakers. With this new focused change approach and facing the future challenges that this endeavor implies; it is possible to launch a new epoch of patient-centered efficaciousness and long-term management of chronic diseases for millions of people worldwide.

References

- Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023). Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. *International Journal of Environmental Research and Public Health*, 20(6), 4732.
- Adadi, A. (2021). A survey on data-efficient algorithms in big data era. *Journal of Big Data*, 8(1), 24.
- Akotaobi, G. C. (2023). Barriers to Storing and Accessing Personal Sensitive Healthcare Data in the Internet Cloud: A Qualitative Study Colorado Technical University].
- Alarcón Garavito, G. A., Moniz, T., Deom, N., Redin, F., Pichini, A., & Vindrola-Padros, C. (2023). The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review. *European Journal of Human Genetics*, 31(3), 282-295.
- Alshehhi, A., Almarzooqi, A., Alhammadi, K., Werghi, N., Tay, G. K., & Alsafar, H. (2023). Advancement in human face prediction using DNA. *Genes*, 14(1), 136.
- Antczak, E., & Miszczyńska, K. M. (2021). Causes of sickness absenteeism in Europe—analysis from an intercountry and gender perspective. *International Journal of Environmental Research and Public Health*, 18(22), 11823.

- Aranda-Anzaldo, A. (2001). Cancer development and progression: a non-adaptive process driven by genetic drift. *Acta Biotheoretica*, 49, 89-108.
- Argollo, M. C., Allocca, M., Furfaro, F., Peyrin-Biroulet, L., & Danese, S. (2019). Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? *Current Pharmaceutical Design*, 25(1), 25-31.
- Arjmand, B., Larijani, B., Sheikh Hosseini, M., Payab, M., Gilany, K., Goodarzi, P., Parhizkar Roudsari, P., Amanollahi Baharvand, M., & Hoseini Mohammadi, N. s. (2020). The horizon of gene therapy in modern medicine: advances and challenges. *Cell Biology and Translational Medicine*, Volume 8: Stem Cells in Regenerative Medicine, 33-64.
- Arokiasamy, P., Salvi, S., & Selvamani, Y. (2021). Global burden of diabetes mellitus. In *Handbook of global health* (pp. 1-44). Springer.
- Berberich, A. J., & Hegele, R. A. (2019). The complex molecular genetics of familial hypercholesterolaemia. *Nature Reviews Cardiology*, 16(1), 9-20.
- Beskow, L. M., Hammack, C. M., & Brelsford, K. M. (2018). Thought leader perspectives on benefits and harms in precision medicine research. *PloS one*, 13(11), e0207842.
- Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D.-T., Vu-Thi, H., & Alzahrani, K. J. (2022). Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. *Journal of Controlled Release*, 343, 703-723.
- Biro, G. P. (2022). Erythrocyte transfusion: brief history and current practice. In *Blood substitutes and oxygen biotherapeutics* (pp. 3-19). Springer.
- Blustein, J. (1993). The family in medical decisionmaking. *The Hastings Center Report*, 23(3), 6-13.
- Bode, A. M., Dong, Z., & Wang, H. (2016). Cancer prevention and control: alarming challenges in China. *National science review*, 3(1), 117-127.
- Bovet, P., & Paccaud, F. (2011). Cardiovascular disease and the changing face of global public health: a focus on low and middle income countries. *Public Health Reviews*, 33, 397-415.
- Bowser, R., & Lacomis, D. (2009). Applying proteomics to the diagnosis and treatment of ALS and related diseases. *Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine*, 40(5), 753-762.
- Burke, W., Zimmern, R. L., & Kroese, M. (2007). Defining purpose: a key step in genetic test evaluation. *Genetics in Medicine*, 9(10), 675-681.
- Bush, C. L., Blumberg, J. B., El-Sohemy, A., Minich, D. M., Ordovás, J. M., Reed, D. G., & Behm, V. A. Y. (2020). Toward the definition of personalized nutrition: a proposal by the American Nutrition Association. *Journal of the American College of Nutrition*, 39(1), 5-15.
- Butnariu, L. I., Gorduza, E. V., Florea, L., Țarcă, E., Moisă, Ș. M., Tradafir, L. M., Cojocaru, E., Luca, A.-C., Stătescu, L., & Bădescu, M. C. (2022). The Genetic Architecture of the Etiology of Lower Extremity Peripheral Artery Disease: Current Knowledge and Future Challenges in the Era of Genomic Medicine. *International journal of molecular sciences*, 23(18), 10481.
- Cacabelos, R., Fernández-Novoa, L., Martínez-Bouza, R., McKay, A., Carril, J. C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., & Nebril, L. (2010). Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. *Pharmaceuticals*, 3(10), 3040-3100.

- Cardon, L. R., & Harris, T. (2016). Precision medicine, genomics and drug discovery. *Human molecular genetics*, 25(R2), R166-R172.
- Clim, A., Zota, R. D., & Tinica, G. (2019). Big Data in home healthcare: A new frontier in personalized medicine. *Medical emergency services and prediction of hypertension risks. International Journal of Healthcare Management*, 12(3), 241-249.
- Cortis, L. J., Ward, P. R., McKinnon, R. A., & Koczwara, B. (2016). Breaking the silos: Integrated care for cancer and chronic conditions. *Cancer and Chronic Conditions: Addressing the Problem of Multimorbidity in Cancer Patients and Survivors*, 287-313.
- De Ferrari, L., Chiappori, A., Bagnasco, D., Riccio, A. M., Passalacqua, G., & Canonica, G. W. (2016). Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? *Expert review of respiratory medicine*, 10(1), 29-38.
- de Freitas Campos, E. I., Gomes, K. B., Ribeiro, D. D., Puurunen, M. K., Oliveira Magalhães Mourão, A. d., Ferreira, I. G., da Costa Rocha, M. O., de Souza, R. P., & Parreiras Martins, M. A. (2023). Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients. *Pharmacogenomics*, 24(13), 701-712.
- De Novellis, D., Cacace, F., Caprioli, V., Wierda, W. G., Mahadeo, K. M., & Tambaro, F. P. (2021). The TKI era in chronic leukemias. *Pharmaceutics*, 13(12), 2201.
- Dugger, S. A., Platt, A., & Goldstein, D. B. (2018). Drug development in the era of precision medicine. *Nature Reviews Drug Discovery*, 17(3), 183-196.
- Duncan, E., Glaros, A., Ross, D. Z., & Nost, E. (2021). New but for whom? Discourses of innovation in precision agriculture. *Agriculture and Human Values*, 38, 1181-1199.
- Elemento, O., Leslie, C., Lundin, J., & Tourassi, G. (2021). Artificial intelligence in cancer research, diagnosis and therapy. *Nature Reviews Cancer*, 21(12), 747-752.
- Fitzgerald, D., Ashcroft, R., Hollin, G., Karkazis, K., King, N. B., Landecker, H., Langlitz, N., Lentzos, F., Meyers, T., & Niewöhner, J. (2020). Lockdown texts. In: Springer.
- Gan, H., Hou, X., Zhu, Z., Xue, M., Zhang, T., Huang, Z., Cheng, Z. J., & Sun, B. (2022). Smoking: a leading factor for the death of chronic respiratory diseases derived from Global Burden of Disease Study 2019. *BMC pulmonary medicine*, 22(1), 149.
- Gannett, L. (2008). The human genome project.
- Gladding, P. A., Legget, M., Fatkin, D., Larsen, P., & Doughty, R. (2020). Polygenic risk scores in coronary artery disease and atrial fibrillation. *Heart, Lung and Circulation*, 29(4), 634-640.
- Gonzalez-Covarrubias, V., Martínez-Martínez, E., & del Bosque-Plata, L. (2022). The potential of metabolomics in biomedical applications. *Metabolites*, 12(2), 194.
- Goulielmos, G. N., Zervou, M. I., Myrthianou, E., Burska, A., Niewold, T. B., & Ponchel, F. (2016). Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients. *Gene*, 583(2), 90-101.
- Gray, I. D., Kross, A. R., Renfrew, M. E., & Wood, P. (2020). Precision medicine in lifestyle medicine: the way of the future? *American Journal of Lifestyle Medicine*, 14(2), 169-186.
- Green, M. J., Peterson, S. K., Baker, M. W., Harper, G. R., Friedman, L. C., Rubinstein, W. S., & Mauger, D. T. (2004). Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. *Jama*, 292(4), 442-452.

- Holman, C. M. (2014). The Critical Role of Patents in the Development, Commercialization, and Utilization of Innovative Genetic Diagnostic Tests.
- Issa, A. M. (2007). Personalized medicine and the practice of medicine in the 21st century. *McGill Journal of Medicine: MJM*, 10(1), 53.
- Jaacks, L. M., Wylie-Rosett, J., & Mayer-Davis, E. J. (2012). Diabetes. *Present Knowledge in Nutrition*, 806-832.
- Jäger, P., Twarock, S., & Haas, R. (2021). Prognostic Parameters in Myeloid Malignancies in a Historical Context—From Microscopy to Individualized Medicine. *Current Drug Targets*, 22(2), 202-213.
- Kamies, R., & Martinez-Jimenez, C. P. (2020). Advances of single-cell genomics and epigenomics in human disease: where are we now? *Mammalian Genome*, 31(5), 170-180.
- Kaur, J., Rahat, B., Thakur, S., & Kaur, J. (2017). Trends in precision medicine. In *Progress and challenges in precision medicine* (pp. 269-299). Elsevier.
- King, R. A., Rotter, J. I., & Motulsky, A. G. (2002). The genetic basis of common diseases. Oxford university press.
- Knoepke, C. E., Chaussee, E. L., Matlock, D. D., Thompson, J. S., McIlvennan, C. K., Ambardekar, A. V., Schaffer, E. M., Khazanie, P., Scherer, L., & Arnold, R. M. (2022). Changes over time in patient stated values and treatment preferences regarding aggressive therapies: insights from the DECIDE-LVAD trial. *Medical Decision Making*, 42(3), 404-414.
- Kohnert, K.-D., Heinke, P., Vogt, L., & Salzsieder, E. (2015). Utility of different glycemic control metrics for optimizing management of diabetes. *World journal of diabetes*, 6(1), 17.
- Kwapisz, D. (2022). Cancer Immunotherapy Clinical Trials. In *Handbook of Cancer and Immunology* (pp. 1-24). Springer.
- Kwong, J. C., McCallum, N., Sintchenko, V., & Howden, B. P. (2015). Whole genome sequencing in clinical and public health microbiology. *Pathology*, 47(3), 199-210.
- Lanza, G., Cali, F., Vinci, M., Cosentino, F. I. I., Tripodi, M., Spada, R. S., Cantone, M., Bella, R., Mattina, T., & Ferri, R. (2020). A Customized Next-Generation Sequencing-Based Panel to Identify Novel Genetic Variants in Dementing Disorders: A Pilot Study. *Neural Plasticity*, 2020(1), 8078103.
- Li, J. (2016). Genetic information privacy in the age of data-driven medicine. 2016 IEEE International Congress on Big Data (BigData Congress),
- Liu, Y., Yeung, W. S., Chiu, P. C., & Cao, D. (2022). Computational approaches for predicting variant impact: An overview from resources, principles to applications. *Frontiers in genetics*, 13, 981005.
- Lovejoy, W. (2000). Ending the genetic discrimination barrier: Regaining confidence in preconception, prenatal, and neonatal genetic testing. *S. Cal. L. Rev.*, 74, 873.
- Mackay, A. J., Kostikas, K., Murray, L., Martinez, F. J., Miravittles, M., Donaldson, G., Banerji, D., Patalano, F., & Wedzicha, J. A. (2018). Patient-reported outcomes for the detection, quantification, and evaluation of chronic obstructive pulmonary disease exacerbations. *American journal of respiratory and critical care medicine*, 198(6), 730-738.
- Maeckelberghe, E., Zdunek, K., Marceglia, S., Farsides, B., & Rigby, M. (2023). The ethical challenges of personalized digital health. *Frontiers in medicine*, 10, 1123863.

- Marwaha, S., Knowles, J. W., & Ashley, E. A. (2022). A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. *Genome medicine*, 14(1), 23.
- Matei, Ș., Cutler, S. J., Preda, M., Dorobanțu, M., Ilinca, C., Gheorghe-Fronea, O., Rădulescu, L., Oprescu, N., Deaconu, A., & Zorilă, C. (2018). The relationship between psychosocial status and hypertensive condition. *Current Hypertension Reports*, 20, 1-13.
- Matera, M. G., Rinaldi, B., Calzetta, L., & Cazzola, M. (2017). Pharmacogenetic and pharmacogenomic considerations of asthma treatment. *Expert opinion on drug metabolism & toxicology*, 13(11), 1159-1167.
- McGuire, W., Horwitz, K., Pearson, O., & Segaloff, A. (1977). Current status of estrogen and progesterone receptors in breast cancer. *Cancer*, 39(6), 2934-2947.
- Mohebbi, A. (2021). A Machine Learning Approach to Treatment Improvement in Type 2 Diabetes using Glucose Data.
- Mohiuddin, A. K. (2020). The role of the pharmacist in patient care: achieving high quality, cost-effective and accessible healthcare through a team-based, patient-centered approach. Universal-Publishers.
- Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2011). A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. *Globalization and health*, 7, 1-11.
- Muir, T., & Zegarac, M. (2001). Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation. *Environmental health perspectives*, 109(suppl 6), 885-903.
- Mundy, C. (2001). The human genome project: a historical perspective. *Pharmacogenomics*, 2(1), 37-49.
- Muthelo, R. G. (2022). An Integrated Decision-making Model for Evaluating Public Sector Construction Bids University of Johannesburg].
- Najjar, R. (2023). Redefining radiology: a review of artificial intelligence integration in medical imaging. *Diagnostics*, 13(17), 2760.
- Ndayishimiye, C., Tambor, M., & Dubas-Jakóbczyk, K. (2023). Barriers and Facilitators to Health-Care Provider Payment Reform—A Scoping Literature Review. *Risk Management and Healthcare Policy*, 1755-1779.
- Ning, C., Jiao, Y., Wang, J., Li, W., Zhou, J., Lee, Y.-C., Ma, D.-L., Leung, C.-H., Zhu, R., & Wang, H.-M. D. (2022). Recent advances in the managements of type 2 diabetes mellitus and natural hypoglycemic substances. *Food Science and Human Wellness*, 11(5), 1121-1133.
- Ohno-Machado, L., Kim, J., Gabriel, R. A., Kuo, G. M., & Hogarth, M. A. (2018). Genomics and electronic health record systems. *Human molecular genetics*, 27(R1), R48-R55.
- Olson, S., & Berger, A. C. (2012). *Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary*. National Academies Press.
- Organization, W. H. (2007). Financing long-term care programmes in health systems, with a situation assessment in selected high-, middle-and low-income countries.
- Organization, W. H. (2013). *Health 2020: A European policy framework and strategy for the 21st century*. World Health Organization. Regional Office for Europe.
- Patel, A., Unni, N., & Peng, Y. (2020). The changing paradigm for the treatment of HER2-

positive breast cancer. *Cancers*, 12(8), 2081.

Perales, S., Torres, C., Jimenez-Luna, C., Prados, J., Martinez-Galan, J., Sanchez-Manas, J. M., & Caba, O. (2021). Liquid biopsy approach to pancreatic cancer. *World journal of gastrointestinal oncology*, 13(10), 1263.

Perkins, B. A., Sherr, J. L., & Mathieu, C. (2021). Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. *Science*, 373(6554), 522-527.

Piette, J. D., List, J., Rana, G. K., Townsend, W., Striplin, D., & Heisler, M. (2015). Mobile health devices as tools for worldwide cardiovascular risk reduction and disease management. *Circulation*, 132(21), 2012-2027.

Pike, E. R., Rothenberg, K. H., & Berkman, B. E. (2014). Finding fault? Exploring legal duties to return incidental findings in genomic research. *The Georgetown law journal*, 102, 795.

RAMEEZ, M., KHAN, A. U., & Ali, R. (2023). BREAKTHROUGHS IN DISEASE PREVENTION AND TREATMENT. *CURRENT STUDIES IN HEALTH AND LIFE SCIENCES*, 431.

Rastegar, S., GholamHosseini, H., & Lowe, A. (2020). Non-invasive continuous blood pressure monitoring systems: current and proposed technology issues and challenges. *Physical and Engineering Sciences in Medicine*, 43, 11-28.

Reichenberg, L. W., & Seligman, L. (2016). Selecting effective treatments: A comprehensive, systematic guide to treating mental disorders. John Wiley & Sons.

Rose, N. (2013). Personalized medicine: promises, problems and perils of a new paradigm for healthcare. *Procedia-Social and Behavioral Sciences*, 77, 341-352.

Roufosse, F. (2018). Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. *Frontiers in medicine*, 5, 49.

Sahu, M., Gupta, R., Ambasta, R. K., & Kumar, P. (2022). Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. *Progress in molecular biology and translational science*, 190(1), 57-100.

Santiago-Rodriguez, T. M., & Hollister, E. B. (2021). Multi 'omic data integration: A review of concepts, considerations, and approaches. *Seminars in Perinatology*,

Sarhene, M., Wang, Y., Wei, J., Huang, Y., Li, M., Li, L., Acheampong, E., Zhengcan, Z., Xiaoyan, Q., & Yunsheng, X. (2019). Biomarkers in heart failure: the past, current and future. *Heart failure reviews*, 24, 867-903.

Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R. P., Banday, S., Mishra, A. K., & Das, G. (2023). Next-generation sequencing technology: current trends and advancements. *Biology*, 12(7), 997.

Schoonmaker, M. M. (1998). Reimbursement issues in genetic testing: The role of the payer in the diffusion of new medical technologies. The Johns Hopkins University.

Schwarz, U. I., Gulilat, M., & Kim, R. B. (2019). The role of next-generation sequencing in pharmacogenetics and pharmacogenomics. *Cold Spring Harbor Perspectives in Medicine*, 9(2), a033027.

Scott, S. L. (2023). A Qualitative Study: Exploring Federal Employees' Perceptions of Barriers to Effective Diversity, Equity, Inclusion, and Accessibility Education in Federal Government Trident University International].

- Shegekar, T., Vodithala, S., & Juganavar, A. (2023). The emerging role of liquid biopsies in revolutionising cancer diagnosis and therapy. *Cureus*, 15(8).
- Shibata, T. (2015). Current and future molecular profiling of cancer by next-generation sequencing. *Japanese Journal of Clinical Oncology*, 45(10), 895-899.
- Singh, D. B. (2020). The impact of pharmacogenomics in personalized medicine. *Current Applications of Pharmaceutical Biotechnology*, 369-394.
- Singh, S. (2023). Racial biases in healthcare: Examining the contributions of Point of Care tools and unintended practitioner bias to patient treatment and diagnosis. *Health*, 27(5), 829-846.
- Singh, S., Sarma, D. K., Verma, V., Nagpal, R., & Kumar, M. (2023). Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. *Biochemical and biophysical research communications*.
- Sitapati, A., Kim, H., Berkovich, B., Marmor, R., Singh, S., El-Kareh, R., Clay, B., & Ohno-Machado, L. (2017). Integrated precision medicine: the role of electronic health records in delivering personalized treatment. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 9(3), e1378.
- Slunecka, J. L., van der Zee, M. D., Beck, J. J., Johnson, B. N., Finnicum, C. T., Pool, R., Hottenga, J.-J., de Geus, E. J., & Ehli, E. A. (2021). Implementation and implications for polygenic risk scores in healthcare. *Human genomics*, 15(1), 46.
- Souhami, R., & Tobias, J. S. (2008). *Cancer and its management*. John Wiley & Sons.
- Squassina, A., Manchia, M., Manolopoulos, V. G., Artac, M., Lappa-Manakou, C., Karkabouna, S., Mitropoulos, K., Zompo, M. D., & Patrinos, G. P. (2010). Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. *Pharmacogenomics*, 11(8), 1149-1167.
- Stampe, K., Kishik, S., & Müller, S. D. (2021). Mobile health in chronic disease management and patient empowerment: exploratory qualitative investigation into patient-physician consultations. *Journal of Medical Internet Research*, 23(6), e26991.
- Stephenson, C. (2011). *The Complementary Therapist's Guide to Conventional Medicine E-Book: The Complementary Therapist's Guide to Conventional Medicine E-Book*. Elsevier Health Sciences.
- Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., & Nice, E. C. (2021). Proteomics, personalized medicine and cancer. *Cancers*, 13(11), 2512.
- Suter, S. M. (2015). Genomic Medicine-New Norms regarding Genetic Information. *Hous. J. Health L. & Pol'y*, 15, 83.
- Tang, W., Li, X., Xie, X., Sun, X., Liu, J., Zhang, J., Wang, C., Yu, J., & Xie, P. (2019). EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. *Lung Cancer*, 136, 6-14.
- Tzvetkov, M., & von Ahsen, N. (2012). Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. *Pathology-Journal of the RCPA*, 44(2), 166-180.
- Viegi, G., Scognamiglio, A., Baldacci, S., Pistelli, F., & Carrozzi, L. (2001). Epidemiology of chronic obstructive pulmonary disease (COPD). *Respiration*, 68(1), 4-19.
- Villagómez-Guzmán, A. K., & Quiroz, I. V. (2024). Human Diseases and Recent Biotechnology Breakthroughs in Curbing Diseases. *Biotechnology and Drug Development for Targeting Human*

Diseases, 9, 165-187.

Vodovotz, Y., Barnard, N., Hu, F. B., Jakicic, J., Lianov, L., Loveland, D., Buysse, D., Szigethy, E., Finkel, T., & Sowa, G. (2020). Prioritized research for the prevention, treatment, and reversal of chronic disease: recommendations from the lifestyle medicine research summit. *Frontiers in medicine*, 7, 585744.

Washington, V., Franklin, J. B., Huang, E. S., Mega, J. L., & Abernethy, A. P. (2023). Diversity, equity, and inclusion in clinical research: a path toward precision health for everyone. *Clinical Pharmacology & Therapeutics*, 113(3), 575-584.

Waterhouse, D., Gelmon, K., Klasa, R., Chi, K., Huntsman, D., Ramsay, E., Wasan, E., Edwards, L., Tucker, C., & Zastre, J. (2006). Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. *Current cancer drug targets*, 6(6), 455-489.

Who, J., & Consultation, F. E. (2003). Diet, nutrition and the prevention of chronic diseases. *World Health Organ Tech Rep Ser*, 916(i-viii), 1-149.

Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górka, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021). Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. *Cancer and Metastasis Reviews*, 40, 949-982.

Wouters, R. H., van der Graaf, R., Rigter, T., Bunnik, E. M., Ploem, M. C., de Wert, G. M., Dondorp, W. J., Cornel, M. C., & Bredenoord, A. L. (2021). Towards a responsible transition to learning healthcare systems in precision medicine: ethical points to consider. *Journal of Personalized Medicine*, 11(6), 539.

Xue, Y., Lameijer, E.-W., Ye, K., Zhang, K., Chang, S., Wang, X., Wu, J., Gao, G., Zhao, F., & Li, J. (2016). Precision medicine: what challenges are we facing? *Genomics, Proteomics and Bioinformatics*, 14(5), 253-261.

Young, A. H., & Grunze, H. (2013). Physical health of patients with bipolar disorder. *Acta Psychiatrica Scandinavica*, 127, 3-10.

Zahid, A., Poulsen, J. K., Sharma, R., & Wingreen, S. C. (2021). A systematic review of emerging information technologies for sustainable data-centric health-care. *International Journal of Medical Informatics*, 149, 104420.

About The Authors

Maria Nazir is an MPhil Scholar of Microbiology at the Cholistan University of Veterinary and Animal Sciences (CUVAS) in Bahawalpur, Pakistan. She is involved in a National Research Program for Universities (NRPU) Project, with research interests in Molecular Characterization. She has submitted abstracts to various conferences and authored and coauthored of several book chapters. Her research focuses on the isolation and Molecular characterization of *Corynebacterium pseudotuberculosis* and their applications in promoting animal health. Her interested research criteria are based on genetics, molecular biology, and bioinformatics.

Email: nazirmaria545@gmail.com

ORCID 0009-0004-6714-6212

Mr. Hameer Khan Khaskheli received his Master's in 2023 from the University of Padova, Italy. He is currently a Research Assistant in the Department of Biomedical Sciences at the University of Padova, Italy. His research expertise spans Molecular Biology, Cancer Biology, Medical Immunology, Stem Cell Research, and Precision Medicine. His primary focus is the intricate regulation of protein phosphorylation by kinases and phosphatases - critical processes often dysregulated in cancer and other diseases. He has an extensive record of publications in prestigious national and international journals and has authored two book chapters with a reputable publisher.

Email: hameerkhan.khaskheli@studenti.unipd.it
9282

ORCID 0009-0002-9622-

Dr. Nighat Batool completed her PhD in Pharmaceutical Sciences from Sargodha University, Sargodha, Pakistan. She is an Assistant Professor of Pharmaceutics at the Pharmacy Department of Pak-Austria Fachhochschule Institute of Applied Science and Technology Mang Haripur. Her research interests include Hydrogels, Microspheres, Pelletisation, Floating tablets, and Controlled release drug delivery systems. She has written more than 17 research articles in well-reputed national and international journals. She has also written book chapters.

Email: nighatbatool2352@gmail.com.

ORCID: 0000-0002-9449-4624

Dr. Rumaisa Nawal received her MBBS degree in 2024 from Multan Medical and dental college. She is a house officer in Bhawal Victoria Hospital, Pakistan. She has done internship program at District Headquarters Lodhran.

Email: rumaisanawal9@gmail.com

ORCID:0009-0000-1903-8365

Minal Hussain graduated from Cholistan University of Veterinary and Animal Sciences in Bahawalpur Pakistan. He continues his postgraduate study in Microbiology from Cholistan University of Veterinary and Animal Sciences Bahawalpur. Her research interest is in Bacteriophages, Bacteriology, Molecular cell biology, and Microbial genetics etc. She has published few book chapters in international journals.

Email: 2019-cu-bios-023@cuvas.edu.pk

ORCID: 0009-0004-0143-5644

Dr. Danish Riaz received his PhD (Zoology) in 2018 from Government College University Faisalabad, Pakistan. He is serving as Assistant Professor of Zoology at the Department of Zoology, Division Science and Technology, University of Education Lahore Pakistan. His research interests include Biological Science with a specialization of animal biotechnology and Fisheries. He has published over 34 research articles in well-reputed national and international journals. He also has written book chapters.

Email: danish.riaz@ue.edu.pk

ORCID-0000-0002-6137-8993

Shafeeq Ur Rehman earned his Bachelor in Applied microbiology from Cholistan University of Veterinary and Animal Sciences (CUVAS) Bahawalpur Pakistan. Currently he is pursuing M. phil in Microbiology from Cholistan University of Veterinary and Animal Sciences (CUVAS) Bahawalpur Pakistan. He is also working as research assistant in a project titled as “Robust Molecular Detection of Silent Circulation of FMD and PPR Viruses in Cholistan as a Model for Disease-Free Zone”. His research interest is in FMD and PPR Viruses, Mucosal Immunity, Virology, Molecular cell biology, Cell culture, Microbial genetics and CRISPR case tools for combating viral diseases. He has published 7 articles and many book chapters in national and international journals.

Email: shafeequrrehmanbhutta@gmail.com

ORCID: 0000-0003-3571-8226

Dr. Muhammad SAFDAR earned his PhD in Molecular Biology and Genetics from Gaziantep University, Turkey. He is Lecturer in the Breeding and Genetics department at Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, Pakistan. His research interests are molecular genetics and genomics, nutrigenomics, nano-genomics, bioinformatics, biotechnology, and their applications. He has published more than 70 research articles in national and international journals. He has also written many book chapters as well as an edited book. He is an associate editor for international journals.

E-mail: msafdar@cucas.edu.pk

ORCID: 0000 0002 3720 2090

To Cite This Chapter

NAZIR M et al., (2024). Revolutionizing chronic disease management with precision medicine and navigating. In *Current Studies in Health and Life Sciences 2024* (pp.103-128). ISRES Publishing.